DJIA 17,156.85 24.88 0.15%
NASDAQ 4,562.19 9.43 0.21%
S&P 500 2,001.57 2.59 0.13%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

37.37 -0.12 (-0.31%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

RHHBY $37.37 -0.31%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $37.46
Previous Close $37.48
Daily Range $37.29 - $37.65
52-Week Range $31.63 - $38.71
Market Cap $210.0B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.4%)
Volume 6,096,131
Average Daily Volume 541,873
Current FY EPS $2.04





Roche Holding Ltd. (ADR) (RHHBY) Description


News & Commentary Rss Feed

Why ImmunoGen, Inc. Stock Crashed 22% in 2014

While the S&P Biotech index soars, ImmunoGen shareholders are getting left in the dust. Find out what's been holding shares back in 2014, and whether or not ImmunoGen will rebound from its current price.

Why Exelixis Inc. Stock Crashed By 70% in 2014

Exelixis stock got mauled after its lead drug failed to impress in a key late-stage study. Find out whether there's any hope left for this biotech stock or if it's time for investors to kiss it goodbye.

Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014

Cancer immunotherapy vaccine developer Inovio Pharmaceuticals has largely underperformed the market in 2014. Find out what's keeping the stock down and whether or not Inovio shares are poised for a rebound.

The Surprising 7 States Where Melanoma Most Often Occurs

Of the seven most common types of cancer, melanoma incidence was the only one to rise between 2000 and 2009. Find out in which seven states melanoma occurs most often, as well as what's being done to curb this terrible form of skin cancer.

Why Exelixis Inc. Stock Plunged

Exelixis' stock is among today's biggest losers after its late-stage prostate cancer trial failed to meet its primary endpoint. See what shareholders should be focused on going forward.

Is It Time to Buy Johnson & Johnson's Stock?

Successful new drug launches have fueled Johnson & Johnson's run, but is there enough left in the tank for shares to continue heading higher?

Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results

Exelixis stock takes one on the chin after the company's lead compound fails to provide a statistically significant survival benefit in a late stage prostate cancer trial. Find out what's next for this highly-followed biotech stock.

InterMune Inc. Shareholders Can Now Breathe Easier Thanks to Roche

Roche stuns Wall Street and investors by snatching up InterMune and its first-in-class lung disease drug. But, does this deal make sense?

Keep Calm and Carry On, Roche Stock

Roche continues to build upon the strongest oncology franchise in Big Pharma but could still use some non-oncology hits

FDA Approves Gilead Sciences Drug for 3 Cancers

The company's tablet, Zydelig, works by blocking signals inside some cancer cells that allow them to grow and survive.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $37.37 (-0.31%)
Current stock: RHHBY
JNJ $106.19 (0.29%)
Current stock: JNJ
NVS $94.72 (0.36%)
Current stock: NVS
GSK $47.10 (-0.42%)
Current stock: GSK